AN2 Therapeutics Inc. Common Stock (ANTX)
Stock · NASDAQ · Health Care
$3.38as of 10/16/2026
Price chart
Active signals
ANTX Signal Track Record
How signals performed across all stocks →What ANTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -2.1% | 38% | September 18, 2026 |
| Bollinger Band Breakout | 19 | +7.7% | 53% | July 30, 2026 |
| Bollinger Band Breakdown | 14 | +0.5% | 50% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -7.7% | 22% | January 23, 2026 |
| Any 20-session window (baseline) | -0.9% | 46% |
Computed by MarketWall from daily closing prices since January 10, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANTX
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigatio…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- www.an2therapeutics.com/
Fundamentals
- 1-day range
- $4.24$4.41
- Market cap
- $218.98M
- P/E (trailing)
- —
- P/E (forward)
- -5.38
- EPS (trailing)
- $-1.07
- Dividend yield
- —
- Beta
- -1.02
- Avg. volume
- 238.8K
Forecasts
2 analyst ratings
AN2 Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANTXAN2 Therapeutics Inc. Common Stock$3.38▼ 6.11%Market cap $218.98MP/E —$1$7.19
- SIGASIGA Technologies Inc. Common Stock$3.17▼ 0.63%Market cap $223.78MP/E —$2.83$8.55
- KROSKeros Therapeutics Inc. Common Stock$10.66▼ 3.96%Market cap $211.16MP/E —$9.69$22.55
- MSLESatellos Bioscience Inc. Common Stock$6.46▼ 5.56%Market cap $209.77MP/E —$7.56$18.98
- GLSIGreenwich LifeSciences Inc. Common Stock$14.55▼ 5.03%Market cap $209.02MP/E —$7.78$34.1
- NERVMinerva Neurosciences Inc Common Stock$2.35▼ 2.89%Market cap $206.85MP/E —$2.31$12.46
- ACIUAC Immune SA Common Stock$2.39▼ 2.45%Market cap $236.11MP/E —$2.1$4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANTX AN2 Therapeutics Inc. Common Stock | $218.98M | — | $3.38 | ▼ 6.11% | $1$7.19 |
| SIGA SIGA Technologies Inc. Common Stock | $223.78M | — | $3.17 | ▼ 0.63% | $2.83$8.55 |
| KROS Keros Therapeutics Inc. Common Stock | $211.16M | — | $10.66 | ▼ 3.96% | $9.69$22.55 |
| MSLE Satellos Bioscience Inc. Common Stock | $209.77M | — | $6.46 | ▼ 5.56% | $7.56$18.98 |
| GLSI Greenwich LifeSciences Inc. Common Stock | $209.02M | — | $14.55 | ▼ 5.03% | $7.78$34.1 |
| NERV Minerva Neurosciences Inc Common Stock | $206.85M | — | $2.35 | ▼ 2.89% | $2.31$12.46 |
| ACIU AC Immune SA Common Stock | $236.11M | — | $2.39 | ▼ 2.45% | $2.1$4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research PartnershipsYahoo · 10/8/2026
- GSK (LSE:GSK) The Latest Update Raises A Bigger QuestionYahoo · 9/30/2026
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKYahoo · 9/28/2026
- AN2 Therapeutics: A Failed Drug Could Become A Major Value DriverSeekingAlpha · 9/22/2026
- AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)Yahoo · 9/16/2026
Insider Activity
Insider Actions →- Trenor Cameron C. III · September 15, 2026 · Grant233.3K
- Trenor Cameron C. III · September 15, 2026 · Grant116.7K
- Readnour Robin Shane · September 9, 2026 · Sale585 @ $6.02
- Readnour Robin Shane · September 9, 2026 · Sale523 @ $6.02
- Readnour Robin Shane · September 8, 2026 · Sale5.3K @ $6.02
- Readnour Robin Shane · September 8, 2026 · Sale4.7K @ $6.02
- Readnour Robin Shane · September 3, 2026 · Sale3.2K @ $6.07
- Readnour Robin Shane · September 3, 2026 · Sale2.9K @ $6.07
- Sarah Joanne Williams · September 1, 2026 · Sale272 @ $5.53
- FitzPatrick Margaret M · September 1, 2026 · Buy2.1K @ $5.53
- Readnour Robin Shane · August 17, 2026 · Sale18.7K @ $6.01
- Readnour Robin Shane · August 17, 2026 · Sale16.7K @ $6.01
- Zakrzewski Joseph S · August 14, 2026 · Gift405.9K
- Kabeer Aziz · July 10, 2026 · Grant2.9K
- Gilbert Lynn Marks · July 10, 2026 · Grant2.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 21.75M
- Total value held
- $74.17M
- Institutional holders
- 50
- Unknown3.15M
- Unknown2.33M
- Unknown2.22M
- Unknown1.66M
- Unknown1.48M
- Unknown1.01M
- Unknown1.00M
- Unknown993.7K
- Unknown749.0K
- Unknown713.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AN2 Therapeutics: Failed Drug Potential Value Driver
Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.
AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.